M31.11 Hematopoietic stem cell transplantation-associated thrombotic microangiopathy [HSCT-TMA]

Name of the Condition

• Hematopoietic stem cell transplantation-associated thrombotic microangiopathy [HSCT-TMA]

Summary

Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a complication of stem cell transplantation characterized by blood clot formation in small blood vessels, leading to reduced blood flow and potential organ damage. It involves microvascular occlusion, often resulting in hemolytic anemia, thrombocytopenia, and organ dysfunction, particularly affecting the kidneys, brain, or gastrointestinal tract.

Causes

HSCT-TMA is caused by abnormalities in blood clotting regulation and vessel integrity triggered by the transplantation process. Contributing factors include endothelial damage from conditioning regimens (e.g., chemotherapy, radiation), immune-mediated reactions, infections, or graft-versus-host disease (GVHD). The exact mechanisms involve complement activation, von Willebrand factor abnormalities, or inflammatory cytokine release.

Risk Factors

• Intensive conditioning regimens (e.g., high-dose chemotherapy, total body irradiation).
• Allogeneic (donor) stem cell transplantation (higher risk than autologous).
• Graft-versus-host disease (GVHD).
• Infections (e.g., viral reactivations, bacterial sepsis).
• Medications (e.g., calcineurin inhibitors, sirolimus).
• Prior history of thrombotic microangiopathy or endothelial injury.

Symptoms

• Fatigue and weakness.
• Bruising or petechiae (small red/purple spots on skin).
• Jaundice (yellowing of skin/eyes).
• Reduced urine output or dark urine.
• Neurological symptoms (e.g., confusion, seizures, headaches).
• Abdominal pain or swelling.
• Shortness of breath or chest pain (if lungs involved).

Diagnosis

Diagnosis relies on clinical evaluation of symptoms, blood tests (e.g., anemia, low platelets, elevated LDH, schistocytes on smear), and assessment of organ function (e.g., kidney or liver tests). Imaging (e.g., MRI, CT) or biopsy may be used to confirm organ involvement. Exclusion of other causes of thrombotic microangiopathy is essential, and criteria often include persistent thrombocytopenia, elevated LDH, and schistocytes without alternative explanations.

Treatment Options

• Supportive care: Blood product transfusions, fluid management, and organ function support.
• Discontinuation or adjustment of offending medications (e.g., calcineurin inhibitors).
• Immunosuppressants or complement inhibitors (e.g., eculizumab) for severe cases.
• Plasma exchange (plasmapheresis) in select patients.
• Management of underlying GVHD or infections if contributing.

Prognosis and Follow-Up

Prognosis varies based on severity, organ involvement, and response to treatment. Early recognition and intervention improve outcomes, but severe cases may lead to organ failure or death. Follow-up includes regular monitoring of blood counts, organ function, and symptom tracking. Long-term surveillance for late complications (e.g., chronic kidney disease) is recommended.

Complications

• Acute kidney injury or chronic kidney disease.
• Neurological damage (e.g., stroke, seizures).
• Gastrointestinal bleeding or perforation.
• Pulmonary involvement (e.g., edema, respiratory failure).
• Multi-organ failure in severe cases.

Lifestyle & Prevention

• Adherence to prescribed medications and transplant protocols.
• Prompt reporting of new symptoms (e.g., bleeding, confusion) to the care team.
• Avoidance of nephrotoxic agents (e.g., NSAIDs) if kidney involvement is present.
• Maintaining hydration and nutrition as advised.

When to Seek Professional Help

Seek immediate medical attention for:

• Sudden confusion, severe headache, or neurological changes.
• Chest pain, shortness of breath, or rapid heartbeat.
• Severe abdominal pain, vomiting, or bloody stools.
• Uncontrolled bleeding or bruising.
• Decreased urine output or dark urine.

Tips for Medical Coders

Document the association with hematopoietic stem cell transplantation clearly in the medical record. Code M31.11 is specific to HSCT-TMA and should be used when the condition is directly linked to the transplantation process. Ensure documentation supports the diagnosis (e.g., timing relative to transplant, clinical findings, and exclusion of other causes) to justify code assignment.